Spyre Therapeutics, Inc. (SYRE): M&A transaction — Aeglea sells global rights to pegzilarginase to Immedica for $15M upfront + up to $100M milestones

Spyre Therapeutics, Inc.

Sold pegzilarginase (for Arginase 1 Deficiency) to Immedica for $15M upfront and up to $100M in milestone payments.
Milestones contingent on European reimbursement decisions and FDA approval of pegzilarginase.
Prior license agreement between Aeglea and Immedica terminated in connection with the sale.
Proceeds net of expenses to be distributed to CVR holders from Spyre merger; first payments expected around Nov 14, 2023.
Marketing Authorisation Application for pegzilarginase under review by the European Medicines Agency.

item 1.01 item 1.02 item 2.01 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Spyre Therapeutics, Inc. completed a disposition involving Immedica Pharma AB for initial payment in cash of $15,000,000 due at Closing and up to $100,000,000 after the Closing (closed 2023-07-27).

Action: disposition
Counterparty: Immedica Pharma AB
Consideration: initial payment in cash of $15,000,000 due at Closing and up to $100,000,000 after the Closing
Closing: 2023-07-27

Exact text from the filing

Subject to the terms and conditions of the Purchase Agreement, at the closing of the transactions (the “Closing”) contemplated by the Purchase Agreement (the “Asset Purchase”), Immedica purchased from the Company its assets related to its research, development and manufacturing program for pegzilarginase for the treatment of Arginase-1 Deficiency as well as other therapeutic, prophylactic, palliative and diagnostic uses (the “Program,” and any pharmaceutical product containing, incorporating or comprising pegzilarginase, the “Product”) for an initial payment in cash of $15,000,000 due at Closing and up to $100,000,000 after the Closing

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Spyre Therapeutics, Inc. terminated License and Supply Agreement with Immedica (effective 2023-07-27).

Action: termination
Agreement: license
Counterparty: Immedica
Effective: 2023-07-27

Exact text from the filing

As previously disclosed on March 21, 2021, the Company entered into a License and Supply Agreement (the “License Agreement”) with Immedica. In connection with the Asset Purchase and pursuant to the Purchase Agreement, the Company and Immedica terminated the License Agreement as of Closing.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Spyre Therapeutics, Inc. entered into Asset Purchase Agreement with Immedica Pharma AB valued at $15,000,000 due at Closing and up to $100,000,000 in Milestone Payments (effective 2023-07-27).

Action: entry
Agreement: asset purchase
Counterparty: Immedica Pharma AB
Value: $15,000,000 due at Closing and up to $100,000,000 in Milestone Payments
Effective: 2023-07-27

Exact text from the filing

On July 27, 2023, Aeglea BioTherapeutics, Inc. (the “Company”) entered into and closed the transactions contemplated by that certain Asset Purchase Agreement (the “Purchase Agreement”) with Immedica Pharma AB

View on SEC.gov

15 m&a transactions filed in the last 30 days. Browse all m&a transactions →

Spyre Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-195289

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.